Cue Biopharma (CUE) said late Tuesday that Chief Financial Officer Kerri-Ann Millar will depart the company on Friday.
Chief Executive Daniel Passeri will expand his role to serve as the interim principal financial and accounting officer until a new appointment is made, the company said in a filing with the US Securities and Exchange Commission.
Cue said it also appointed Jill Broadfoot to the board, the corporate governance and nominating committee of the board, and as chairman of the board's audit committee.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.